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Abstract:  
Background and Aims: Moderate cure rates of acute hepatitis C virus 
(HCV) infections with pegylated interferon and ribavirin (PR) have been 
described in the last decade in men who have sex with men (MSM) who 
are coinfected with the human immunodeficiency virus (HIV). However, 
a subsequent high incidence of HCV reinfections has been reported 
regionally in men who both clear the infection spontaneously or who 
respond to treatment. 
Methods: Retrospective analysis of reinfections in HIV infected MSM in 
eight centers from Austria, France, Germany, and the UK within the 
NEAT network between May 2002 and June 2014. 
Results: Of 606 individuals who cleared HCV spontaneously or were 
successfully treated, 149 (24.6%) presented with a subsequent HCV 
reinfection. 30 out of 70 (43%) who cleared again or were successfully 
treated, presented with a second reinfection, 5 with a third, and one 
with a fourth reinfection. The reinfection incidence was 7.3/100 
person-years (95% CI 6.2-8.6). A trend for lower incidence among 
individuals who had spontaneous cleared their incident infection than 
among individuals who were treated was found (Hazard ratio 0.62, 
95% CI 0.38-1.02, p=0.06). Spontaneous clearance of reinfection was 
associated with ALT levels >1000 IU/ml and spontaneous clearance of a 
prior infection. 
Conclusions: HCV reinfection is an issue of major concern in HIV-
positive MSM. Prevention strategies are needed for high-risk groups to 
reduce morbidity and treatment costs. HIV-positive MSM with a prior 
  
 5
HCV-infection should be tested every 3 to 6 months for reinfection, 
those who had achieved a reinfection every 3 months. 
Keywords: HCV reinfection, acute hepatitis C, HIV-HCV coinfection, SVR, 
spontaneous clearance, HCV therapy 
 
Lay summary: We evaluated the occurrence of HCV reinfection in HIV-
positive men who have sex with men who were cured for a previous 
HCV infection. We found an alarming incidence of 7.3/100 person-
years. Prevention measures need to address this specific subgroup of 
patients at high risk for HCV. 
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Introduction 
Liver disease represents a major cause of morbidity and mortality 
among patients infected with the human immunodeficiency virus (HIV) 
in the developed world(1). In the setting of effective combined 
antiretroviral therapy (cART) and the successful preservation of a 
patient´s immune function, chronic infection with hepatitis C virus 
(HCV) is currently the main cause for liver related mortality due to liver 
failure and hepatocellular carcinoma(2, 3).  
In recent years, HCV seroconversions within European HIV cohorts 
have been reported among people who inject drugs (PWID) and men 
who have sex with men (MSM)(4, 5). In the case of the MSM community, 
several outbreaks of acute HCV infection have been described in 
Western metropolitan areas over the last decade associated with high-
risk sexual practices, genital ulcer disease and recreational drug use 
including parenteral administration(6-8). Treatment uptake with 
interferon-based therapy has generally been high in the HIV-positive 
MSM population and high SVR rates have been reported as many, if not 
most, are treated in the acute infection phase(9). Yet despite these 
outcomes the epidemic has continued unabated (5, 10). 
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Several new direct-acting antivirals (DAAs) have been approved for 
interferon-free treatment of chronic HCV in Europe. Most of these 
agents are characterized by a favorable interaction profile with 
antiretroviral medication and sustained virological response (SVR) 
rates above 90% in clinical trials in the HIV/HCV coinfected 
population(11-14). Mathematical modeling predicts substantial 
reductions in HCV prevalence in HIV infected MSM within a decade(15) 
(16)if the required scale-up in treatment uptake with these new 
compounds is achieved. Further benefits have been predicted if 
treatment is combined with an intervention to reduce behavioral risk, 
which makes the eradication of HCV an achievable goal in the HIV-HCV 
coinfected population in Western Europe. 
In the presence of maintained risk behavior, HCV reinfections have been 
described in PWID and MSM who either cleared their initial infection 
spontaneously or were successfully treated with interferon-based 
therapies(17-20). In a recent meta-analysis of 61 studies, the five-year 
risk of HCV reinfection in HIV infected MSM was as high as 15% and 
higher than in studies on PWID(21). Two studies to date have described 
reinfection incidence among HIV-HCV coinfected MSM with reported 
rates of 8-15 per 100 person-years (py)(19, 22). More recently, HCV 
reinfections have also been reported in phase 3 trials of DAA HCV 
compounds(12, 14, 23) nearly all of which have occurred among HIV 
infected MSM. 
Data from London reported that individuals who spontaneously clear 
their acute infection may be at lower risk of future HCV reinfection 
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when compared to those who are treated and achieve SVR. This 
indicates that a degree of protective immunity may develop for some 
patients(19). An effective immune response against HCV through 
multiple infections has been shown in animal models(24); however, 
studies among PWID have failed to consistently demonstrate a 
protective effect(18, 25). 
An accurate description of the HCV epidemic including a concise 
observation of reinfections in specific populations will be crucial to 
achieve the goal of HCV eradication and to reduce costs of repeated DAA 
treatment. This study quantifies the rate of HCV reinfections among HIV 
infected MSM from seven urban European areas and investigates 
potential variables associated with repeat spontaneous viral clearance. 
 
Methods 
The dataset for this analysis was merged from eight centers in four 
countries within the NEAT (European AIDS Treatment Network) 
consortium: The Chelsea and Westminster Hospital and the Royal Free 
Hospitals, London, the St. Antoine Hospital, Paris, the Center for 
Infectiology, Berlin, the Center for Infectious Medicine Hamburg, the 
Center for HIV and Hepatogastroenterology, Duesseldorf, the University 
Hospital Bonn, and the Medical University of Vienna.  
In all centers, the available data have been homogenized due to 
previous collaborations such as the NEAT Probe-C cohort.  
All HIV-positive MSM from these centers with a history of a cured first 
HCV infection were identified with subsequent HCV PCR results 
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followed through time to detect reinfection. 
HCV cure was defined as follows: 
• Patients with SVR defined by a negative HCV PCR at least 12 
weeks after the end of an interferon-based treatment and at least 
1 subsequent HCV PCR measurement. 
• Patients with a spontaneously cleared HCV infection, defined by 
at least two negative HCV PCR measurements at least 24 weeks 
apart following HCV infection. 
 
The following data were collected for all patients: Age, date of diagnosis 
of acute HCV infection, HCV genotype, date of HCV cure, whether cure 
was a result of treatment or spontaneous clearance, and date of last 
follow-up visit. 
HCV RNA measurements were not standardized and depended on local 
operating procedures which ranged between once per year and every 
three months and in the case of newly developed ALT elevation. 
Reinfection was defined as a detectable HCV RNA at any timepoint after 
cure, or within the above mentioned time frames, if a HCV geno-
/subtype switch occurred. In men who had a reinfection episode, the 
following data was obtained at the first HCV infection and at each new 
infection episode: age, duration of HIV infection, date of first HCV 
infection, HCV genotype, HCV viral load at diagnosis, maximum alanine 
aminotransferase (ALT), CD4 cell count, HIV viral load, HIV treatment 
status. Date of HCV cure, whether cure was as a result of treatment or 
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spontaneous clearance and date of last follow-up visit were further 
collected. 
In patients who achieved multiple SVRs or spontaneous clearances, the 
time-point of subsequent reinfections and the described variables were 
documented. 
Reinfection incidence was calculated using Kaplan-Meier survival time 
methods. The start of follow up was defined as the date of end of HCV 
treatment for individuals who were successfully treated and as the first 
negative HCV-RNA PCR for individuals who spontaneously cleared their 
infection. For individuals that underwent reinfection, the date of failure 
was taken as the date of newly positive HCV RNA PCR. Individuals who 
did not undergo reinfection were censored at the date of last negative 
HCV PCR available. Comparison of reinfection incidences were 
calculated using logrank test and cox proportional hazards model. 
Variables associated with  spontaneous clearance of reinfection were 
evaluated using logistic regression. Continuous variables were grouped 
(Age: </>30, ALT </>1000 IU/ml at initial infection and reinfection, 
HCV VL of 1st infection </> 500000 copies/ml, HIV VL undetectable at 
1st infection, CD4 at first infection by brackets of 100 cells/ml, CD4 at 
reinfection by brackets of 100 cells/ml). All variables that had an 
association with a p-value <0.1 were further explored for association 
using multiple logistic regression. Only age and initial infection 
outcomes were available for regression with reinfection as the outcome. 
McNemar’s test was used to compare the spontaneous clearance 
proportions for the 1st and 2nd reinfections. All analyses were 
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performed using Stata version 12.0. 
 
Results 
606 HIV-positive MSM with a documented cure of HCV infection 
between May 2002 and February 2014 were identified. SVR following 
treatment with pegylated interferon +/- ribavirin was achieved in 494 
(81.5%) men, while 111 (18.3%) exhibited spontaneous viral clearance, 
and in one patient the type of cure was not documented.  
During follow up until June 2014, 149 of these men (24.6%) presented 
with a de-novo acute HCV reinfection episode. In 95% (135/142) of 
cases, an ALT elevation above 41 IU/mL was observed. 
The median CD4 cell count at reinfection was 533/mm3 (IQR 412-760) 
and 82% of reinfected patients had an HIV viral load less than 50 
copies/ml at time of reinfection. The median duration of diagnosed HIV 
infection at HCV reinfection was 9 years (IQR 6-14). 70 patients had a 
documented cure or spontaneous clearance of their first reinfection of 
which 30 (43%) presented with a second reinfection a median of 1.8 
years (IQR 1.2-2.4) after clearance of their prior infection. Five patients 
had a third reinfection, and in one patient a fourth reinfection occurred. 
Table 1 shows details of primary and reinfection genotypes, ages, SVR 
proportions and spontaneous clearance proportions. 
 
Reinfection incidence 
In calculating reinfection incidence, 54 patients from 3 centers were 
excluded due to incomplete datasets (no date for end of follow up, no 
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date for start of follow up, incorrectly entered end of follow up date). 
552 patients were therefore included in the analysis representing 1952 
person-years (py) of follow-up with a median follow up time of 3.0 
years (IQR 1.6-4.9, min 0.02/max 11.4 years).  
The overall median follow-up time was 3.0 years (interquartile range 
(IQR) 1.6-4.9 years). 
In total, 143 HCV reinfections occurred at a rate of 7.3/100 person-
years (95% confidence interval (CI) 6.2-8.6). The median duration to 
reinfection was 2.0 years (IQR 1.1-3.3 years). There was a trend for 
higher reinfection incidence among individuals who achieved SVR 
following treatment for their incident infection (7.8/100 py) compared 
to reinfection incidence among individuals who had spontaneously 
cleared their incident infection (4.9/100 person-years; crude 
unadjusted hazard ratio for reinfection 0.62, 95%-CI 0.32-0.95, P = 
0.06). Figure 1 is the Kaplan-Meier curve showing survival from 
reinfection for all patients with 95% confidence intervals. 
Sixty-four men either spontaneously cleared or were successfully 
treated for their subsequent HCV reinfection and had follow up data 
available representing 143 py of follow up (Median follow up 1.8 years 
IQR 0.9-2.8). Of these 64 men, 27 presented with a second reinfection at 
a median of 1.7 years (IQR 1.2-2.4) after cure of the prior infection. The 
second reinfection incidence rate was significantly higher than the first 
reinfection incidence at 18.8/100py (95% CI 12.9-27.5; hazard ratio for 
second reinfection 2.51, 95% CI 1.7-3.8, p<0.001). 
Table 2 depicts the reinfection incidence per center, with the highest 
  
 13 
being in Paris (21.8/100py, 95% CI 11.3-41.8), followed by Vienna 
(16.8/100py, 95%CI 8.7-32.3), Berlin (8.2/100py, 95% CI 5.6-12.1), 
Duesseldorf (8.1/100py, 95% CI 4.6-14.3), and London/Chelsea 
Westminster (7.0/100py, 95% CI 5.3-9.1). The lowest in incidence rate 
was seen in Hamburg (5.0/100py, 95% CI 2.9-8.7). The incidence rate 
decreased only slightly over time (Figure 2). 
 
Spontaneous clearance rates 
Twenty-one of 135 patients (15.6%) spontaneously cleared their first 
reinfection and 7 of 22 patients (28.6%) spontaneously cleared their 2nd 
reinfection (p=0.43 for increase in spontaneous clearance proportion). 
Men who spontaneously cleared their incident infection were less likely 
to present with a subsequent reinfection episode than men who had 
achieved SVR to their incident infection (OR 0.52, 95% CI 0.29-0.91, 
p=0.02). In multivariable analysis, spontaneous clearance of the first 
HCV infection (OR=7.47, 95%CI 1.9-29.2, p=0.004) and a maximum ALT 
level above 1000 IU/mL (OR=13.9, 95%CI 4.3-45.4, p<0.001) were 
associated with spontaneous clearance of the reinfection(26). 
 
Discussion 
This is the largest cohort of HIV infected MSM patients followed-up 
longitudinally for HCV reinfections after initial HCV cure. We found a 
high reinfection incidence of 7.3/100py with an estimate that almost 
one third of patients being reinfected after 5 years. These numbers 
highlight the failure of current prevention strategies and the need for 
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specific measures in the HIV-infected MSM population at risk in Europe. 
With a high treatment uptake in this population even in the interferon 
era and with higher response rates to treatment in the acute phase of 
infection(27), reinfections are occurring most likely due to maintained 
risk behaviors. As new, well tolerated, but costly HCV treatments have 
become the standard of care for HCV therapy, there is an urgent need to 
develop strategies to prevent reinfection at such scale. It is essential to 
expand testing opportunities to identify at the earliest opportunity men 
in the early stages of infection to prevent onward transmission of 
infection through treatment and behavioral interventions. The men 
included in this study were all linked to care where if retained in care 
they are closely monitored and frequently tested for HCV reinfection 
using HCV RNA. Rapid access to effective treatment in conjunction with 
interventions to reduce high risk behaviours are then required. 
The mode of transmission is not entirely understood in this population, 
but seems to occur in the setting of HIV infection, potential traumatic 
sexual practices with increased risk of blood-blood contact, and 
increasing recreational drug use including intravenous administration, 
commonly referred to as “Chemsex”(28). “Chemsex” is defined as the 
use of sexually disinhibiting recreational drugs to facilitate sexual 
sessions lasting often several days with multiple sexual partners and 
which put men at high risk of infection with HCV and other STIs(29). 
Our patients had a median age of 41 years at their first reinfection and 
well-controlled HIV infection, indicating that they were aware and 
compliant to health interventions, but potentially also driving their 
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willingness for unprotected and/or chemically enhanced sex. The 
dramatic incidence rate observed here confirms on a European level 
what has previously been reported (19, 20, 22) on a regional level. 
Studies in PWID, all much smaller than the number of included 
individuals in this study, have shown HCV reinfection incidence rates 
between 0.8 and 4.7 per 100 person-years(30). In a meta-analysis 
performed by Aspinall et al. the pooled reinfection incidence in those 
reporting intravenous drug use after HCV cure was 6.44 (95% CI, 2.49-
16.69) per 100 py(31). Hill et al. reported a five-year risk for HCV 
reinfection of 10.6% in PWID whilst it was over 15% in MSM(21). These 
findings underline the need for risk-adapted interventions during 
follow-up post HCV cure. HIV-positive MSM with a history of HCV 
infection and especially those presenting with an HCV reinfection 
require close monitoring and behavioral interventions to reduce the 
risk of reinfection. 
We observed large regional differences in reinfection incidence within 
our dataset, with the highest being in Paris (21.8/100 patient-years) 
and the lowest being in Hamburg (5.04/100 patient-years). These 
differences may reflect the lack of precision in the incidence estimates 
from the smaller centers due to lower numbers of men included in the 
dataset and the shortest follow-up time or it may represent specific risk 
behavior patterns in men seen in the different centers, rather than 
absolute differences in incidences in the regions. 
The reinfection incidence rates increased from the first reinfection 
(7.3/100py, 95% CI 6.2-8.6) to the second reinfection (18.8/100py, 
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95% CI 12.9-27.5, p<0.001). This indicates a maintained risk behavior 
in a potentially specific high-risk group, who require urgent targeting 
for prevention measures related to risk behaviors. How often these 
individuals require testing for HCV infection de novo is unclear but the 
present suggestion that this occurs annually does not appear sufficient, 
and we suggest HCV RNA testing every three to six months after an 
incident HCV infection and every three months in patients that had 
been reinfected. 
We found a spontaneous HCV clearance rate of 15.6% at the first 
reinfection episode consistent with findings from others in HIV-HCV-
coinfected populations(26). However, at second reinfection the 
spontaneous clearance rate showed a non-significant increase to 28.6%. 
Individuals who had spontaneously cleared their initial infection were 
more likely to spontaneously clear (p=0.004) their reinfection, and 
there was also a trend for lower reinfection incidence for people who 
had spontaneously cleared their initial infection compared to those that 
were treated (HR 0.62, 95% CI 0.38-1.02, p=0.06). These findings would 
suggest the development of a degree of HCV-specific immunity with 
repeated exposure, which has been previously demonstrated in humans 
and chimpanzees(24, 25). The absence of this observation in the setting 
of in PWID may be explained by the type or frequency of HCV exposure, 
or the testing interval(32). 
Several mechanisms of the host´s immune response have been 
associated with spontaneous HCV clearance, including interferon-
mediated natural killer (NK) cell response(33), a broad multispecific 
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CD4 T cell response(34), neutralizing antibodies(35), and the presence 
of specific HLA epitopes(36).  
The ability to clear an acute HCV infection spontaneously is reduced in 
HIV-infected patients probably due to a compromised immune 
response. Factors such as female sex(37), coinfection with hepatitis B 
virus, a favorable IL28B genotype(38), and a higher CD4 cell count have 
been associated with clearance in clinical cohorts, as well as higher ALT 
levels, higher bilirubin levels, a faster decline in HCV viral load(26), and 
a less diverse viral quasispecies(39). Likewise, in this study, ALT levels 
above 1000 IU/mL were associated with spontaneous clearance as it 
has been described by other groups(26). These observations potentially 
reflect a stronger and more directed immune response against HCV in 
those who clear spontaneously. It remains however unclear why we 
observed spontaneous clearance in those with their first reinfection 
that did not clear the succeeding infection. 
This study has a number of limitations. First of all, the retrospective 
nature of the study limits the conclusions that may be drawn from the 
analysis. In addition, detailed patient information was only available for 
men that acquired reinfection, limiting the analysis of risk. We may 
have underestimated the number of reinfections as those that cleared 
their infection within testing intervals may have been missed. On the 
other hand, false positive HCV RNA assay may have led to 
overestimation of cases. The HCV-RNA PCR testing interval was not 
standardized across centers and depended largely on the treating 
physician or national guidelines. But we believe that reasonable HCV-
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RNA PCR testing would have been performed as all our patients were 
HIV-seropositive MSM with a high grade of linkage-to-care and regular 
medical visits at experienced STD centers/HIV outpatient clinics, 
usually every three months. Some datasets were incomplete leading to 
exclusion from detailed analysis. In addition, the majority of centers did 
not routinely test for IL28B genotype substantially limiting the analysis 
of this factor for risk of reinfection and spontaneous clearance. 
Our study lacks detailed behavioral information, notably on injection 
drug use in this population, which hampers conclusions on prevention 
efforts. 
Phylogenetic analysis was not performed in our cohort, and nearly half 
were reinfected with the same HCV subtype. Others have described a 
prolonged fluctuating viraemia that may be confounded with a new HCV 
infection(18). However, our patients were nearly exclusively diagnosed 
as acute HCV infection and the median ALT levels at reinfection were 
302 and 268 IU/ml at the first and second reinfection, which makes 
chronic infection less likely. As we included treated patients and did not 
perform next-generation sequencing, we can not rule out the re-
emergence of a resistant minority variant as has been previously 
postulated(40). However, the high treatment response rates and high 
spontaneous clearance rates in our patients` succeeding episodes make 
this hypothesis unlikely. 
 
Conclusions 
HCV reinfection is a critical health concern among HIV infected MSM 
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and frequently occurs after successful treatment or spontaneous 
clearance of acute HCV infection. Prevention strategies – both treatment 
and behavioral – are needed to target high-risk groups to reduce 
morbidity and treatment costs. Patients as well as clinicians have to be 
aware of the specific risk-behavior in this setting and counseling should 
be accompagnied by behavioral interventions to avoid reinfections. 
HIV-positive MSM with a prior HCV-infection should be regularly tested 
for reinfection. The increase in spontaneous clearance rates observed in 
our cohort indicates a possible increase of HCV-specific responses with 
repeated infection. 
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Figure 1: Kaplan Meier showing estimates for the proportion of HIV 
positive MSM surviving free from HCV reinfection following 
spontaneous clearance or treatment of an initial HCV infection over 
time 
 
Figure 2: HCV reinfection incidence in Western Europe over time. 
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Table 1: Baseline characteristics at incident infection and reinfection 
 
 Incident Infection 1st Reinfection 2nd Reinfection 
Number included N/A 606 70 
Number of 
reinfections (%) 
606 149 (24.6) 30 (42.9) 
Genotypes GT1 376(70.5) 
GT2 13(2.4) 
GT3 46(8.6) 
GT4 96 (18) 
Mixed GT1,3 – 2(0.4) 
GT1 
104(73.2) 
GT2 1(0.7) 
GT3 12(8.5) 
GT4 
25(17.6) 
GT1 23(85.2) 
GT2 0 
GT3 1(3.7) 
GT4 3(11.1) 
Proportion with 
genotype switches 
N/A 71/136 (52) 14/26 (54) 
Median age (IQR) 39 (34-44) 41 (37-45) 42 (40-48) 
Proportion that 
clear spontaneously 
(%) 
N/A 21/135 
(15.6%) 
7/22 
(28.6%) 
SVR proportion (%) N/A 76/108 (70) 12/13 (92) 
 
Table 2: HCV reinfection incidence among HIV positive MSM by location 
in Western Europe 
Centre 
Incidence reinfections/100py 
(95% CI) 
Number of 
reinfections 
Person years 
follow up 
Duesseldorf 
(n=59) 
8.1 (4.6-14.3) 12 148 
Hamburg 
(n=73) 
5.0 (2.9-8.7) 13 258 
Berlin 
(n=95) 
8.2 (5.6-12.1) 26 316 
Bonn 
(n=11) 
4.8 (0.7-33.7) 1 21 
London – 
Chelwest 
(n=190) 
7.0 (5.3-9.1) 52 746 
London – 
Royal Free 
(n=69) 
5.7 (3.7-8.7) 21 369 
Paris 
(n=27) 
21.8 (11.3-41.8) 9 41 
Vienna 
(n=28) 
16.8 (8.7-32.3) 9 54 
 
 
 
 
 
  
 
 
 
 
Time period Person years follow up Number of reinfections Reinfection incidence, 
per 100py (95% CIs) 
2002-2006 151 13 8.6 (5.0-14.8) 
2006-2010 666 54 8.1 (6.2-10.6) 
2010-2014 1119 76 6.8 (5.4-8.5) 
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